Search for: "Newman, Appeal of" Results 1221 - 1240 of 1,629
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Sep 2011, 3:27 pm
On appeal, Leithem argued that the prior art did not fluff the pulp. [read post]
16 Sep 2011, 5:25 am by Stefanie Levine
This decision was appealed to the Supreme Court and subsequently remanded to the CAFC after the Supreme Court's Bilski decision. [read post]
16 Sep 2011, 5:25 am by Stefanie Levine
This decision was appealed to the Supreme Court and subsequently remanded to the CAFC after the Supreme Court's Bilski decision. [read post]
12 Sep 2011, 8:35 am by admin
  Remember, the ‘maze of derivatives’ could be appealing to public officials only if they thought, against all common sense, that somehow the derivatives were economic phlogiston, lowering costs without risk or payments. [read post]
12 Sep 2011, 3:35 am by Marie Louise
(IPBiz)   US Patents – Decisions CAFC reverses DNH in Markem-Imaje Corporation v Zipher; Newman partially dissents (IPBiz) District Court Nevada: Plaintiff need not produce licenses involving unasserted patents where licenses involving patents-in-suit have been produced: Bally Technologies, Inc. v. [read post]
10 Sep 2011, 10:27 am
. '572 owner Zipher appealed, where CAFC Judges Clevenger and Linn got chided by Judge Newman for illiteracy, a remarkable feat considering the extensive parsing of the spec in the majority opinion. [read post]
10 Sep 2011, 9:20 am by Lawrence B. Ebert
”Judge Newman dissented on the second point about tension measurement:I concur in Part I of the court’s decision. [read post]
7 Sep 2011, 8:03 am by Stephen Jenei
.”  ~Jack Handey Chief Judge Rader, joined by Circuit Judge Newman, offered their own deep thoughts in a concurring opinion on Classen Immunotherapies, Inc. v. [read post]
6 Sep 2011, 1:10 pm by Stephen Jenei
Court of Appeals for the Federal Circuit has once again taken up the burden to review the case of Classen Immunotherapies, Inc. v. [read post]
1 Sep 2011, 8:31 am by Stefanie Levine
The Federal Circuit first decided Classen’s appeal in 2008, when a panel comprised of Circuit Judges Newman and Moore and District Judge Farnan (sitting by designation) held in a one-paragraph, non-precedential decision authored by Judge Moore that Classen’s claims do not satisfy 35 USC § 101. [read post]
1 Sep 2011, 8:31 am by Stefanie Levine
The Federal Circuit first decided Classen’s appeal in 2008, when a panel comprised of Circuit Judges Newman and Moore and District Judge Farnan (sitting by designation) held in a one-paragraph, non-precedential decision authored by Judge Moore that Classen’s claims do not satisfy 35 USC § 101. [read post]
1 Sep 2011, 7:00 am by Jeffrey Krivis
Newman firmly believed in the benefit of ‘creative chaos. [read post]
31 Aug 2011, 1:27 pm by Rantanen
  On initial appeal, the CAFC affirmed, with Judge Moore penning an extremely short affirmance. [read post]
29 Aug 2011, 3:28 pm by Lawrence B. Ebert
Judge Newman's dissent in the case begins: On this appeal from a PTO rejection, the court has ap- plied a new ground of rejection—which the court calls “indefiniteness”—and issued a final judgment on that ground, although the applicant has had no opportunity to respond to the rejection. [read post]
29 Aug 2011, 11:38 am by Dennis Crouch
On appeal to the Court of Appeals for the Federal Circuit, a split panel agreed that the claims lacked merit but found them impermissibly indefinite rather than anticipated. [read post]
27 Aug 2011, 7:55 pm
. '392 was found valid, both at district court, and on appeal, where the CAFC set its own formula for chemical obviousness - for this case at least. [read post]
27 Aug 2011, 7:26 am by Steve Statsinger
August 12, 2011) (Newman, Calabresi, Hall, CJJ) Former defense attorney Robert Simels appealed his conviction, after a jury trial, of various counts relating to a witness-tampering scheme, and his fourteen-year sentence. [read post]
25 Aug 2011, 8:14 am by Lawrence B. Ebert
Patent and Trademark Office (“Patent Office”) and to errors in Table 3 of the ’392 patent, the same conduct upon which Apotex premised some of its inequitable conduct claims at issue in this appeal. [read post]